🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Not only quantity, but quality. Travail admirable et inspiration pour beaucoup.

Looking good guys!

Terrific overview of a broad topic. Personalized medicine in IBD. It is indeed a privilege to get to know our patients long-term Also Dr Dermot McGovern happened to have the coolest zoom background this morning. Dr Dermot McGovern Andres Yarur #CCCongress22

#MondayNightIBD Elizabeth A Spencer MD MS Aline Charabaty, MD, FACG, AGAF Benjamin Gold Michael J Rosen, MD, MSCI Rafeeq Hilary Michel MD Eric Benchimol David Ziring Jeremy Adler, MD, MSc Jordan Shapiro, MD, MS Maria Oliva-Hemker, MD Precision medicine is the Loch Ness monster of IBD Everybody talking or writing about it but nobody has seen it !🤪

Andres Yarur presents great data showing PO MTX (not just IM!) and elevated 6-TG levels > 146 are associated with favorable PK profiles and outcomes in IFX but not VDZ or UST (though outcomes numerically improved in combo UST pts) - important knowledge gap!

Gil Y. Melmed, MD, MS presenting our data on Cellular and humoral responses to mRNA vaccines vs SARSCOV2 in IBD patients. Thanks to collaborators across US and patients for volunteering and engaging. #DDW2022 Cedars-Sinai Academic Medicine IBD at Cedars-Sinai 🧵

Take homes- 1. Antibodies lower in IBD vs non-IBD but 99% had good AB levels. 2. No difference in TCR sequence breadth & depth between IBD & non-IBD. Summary: reassuring for IBD community & ? booster strategies for IBD should be same as other populations. NB data are pre-omicron!

Dose optimisation for #Vedo in primary NR @ week 6 with high clearance doesn’t improve response rates Clinically relevant results from ENTERPRET Trial 🔑 receptor occupancy ? Andres Yarur #DDW2022

2/3 Double dose vedolizumab (600mg) at week 6 and subsequent Q4 week dosing does not improve outcomes in high clearance patients (low TDM at week 5) Andres Yarur

3/3 Combination therapy with thiopurines or MTX does not improve clinical or pharmokinetic outcomes with VDZ or UST, but still important for IFX Andres Yarur

Exactly. Everyone is fixated with TL thresholds. Heterogeneity in assays is enough to avoid using a “universal” number.

Who's ready for our 23rd Annual Educational Meeting in #Gastroenterology? #CedarsSinai #CME #GITwitter Click here to learn more: cedars.cloud-cme.com/gastroenterolo…

Thank you everyone for your kind words and overwhelming support. It is a real honor to receive this recognition. I hope we continue to work all together to advance knowledge and care. Grateful to work and share with so many talented people. Collaboration and team work is key!

The October's Editors Essential Reading finds combination therapy with immunomodulators improves the pharmacokinetics of infliximab but not vedolizumab or ustekinumab. To read the full article, click the link ➡️ ow.ly/QH2z50PPV3x

Yes. I agree.

Dr. Deepak came all the way to Los Angeles (on his birthday) to talk to us about one of the most challenging CD complications: Peri-Anal Crohn’s disease. Parakkal Deepak MD, MS, FACG

Thank you Steve Hanauer for decades of leading the IBD world and educating us all Millie Long Miguel Regueiro

🤩 to start 3-year study funded Helmsley Charitable Trust on 'GLP-1R Agonists to Promote Epithelial Healing in Crohn’s disease' with #LouisCohen Andres Yarur WashU Medicine Division of Gastroenterology WashU Medicine Inflammatory Bowel Disease Center Mount Sinai IBD Center IBD at Cedars-Sinai Deepak Lab with detailed metabolic analyses mountsinai.org/about/newsroom…

Corey Siegel summarizing positioning of pharmacologic therapies in IBD at the annual Cedars Sinai Symposium.

Exclusive enteral nutrition can induce #IBD remission but it can be hard to do. My tips 4 the #MD & #RD rdcu.be/vAJC #AmJGastro